Keyphrases
Liraglutide
77%
Heart Failure Patients
70%
Polycystic Ovary Syndrome
66%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
62%
Anabolic Steroids
55%
Chronic Heart Failure
49%
Natriuretic Peptides
49%
Heart Failure
45%
Randomized Clinical Trial
44%
Abusers
44%
Copeptin
39%
Systolic Heart Failure
36%
Confidence Interval
36%
Atrial Natriuretic Peptide
34%
Randomized Placebo-controlled Trial
33%
Visceral Adipose Tissue
30%
Type 2 Diabetes Mellitus (T2DM)
27%
Placebo
27%
MR-proADM
26%
Insulin Resistance
26%
Cardiovascular Disease
24%
Left Ventricular Function
24%
Cardiovascular Biomarkers
24%
Testosterone
23%
Left Ventricular Ejection Fraction
23%
Type 2 Diabetic Patients
23%
Galectin-3 (Gal-3)
22%
Adrenomedullin
22%
Orchiectomy
22%
Hyperprolactinemia
22%
Body Composition
21%
Cardiac Function
21%
Androgen Deprivation Therapy
19%
Fat Mass
18%
Renal Function
18%
Neurohormonal Activation
17%
Non-alcoholic Fatty Liver Disease (NAFLD)
17%
Placebo-controlled
17%
Plasma Concentration
16%
Liver Fat Content
16%
Glucagon-like
15%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Liraglutide
66%
Placebo
61%
Brain Natriuretic Peptide
58%
Ovary Polycystic Disease
55%
Natriuretic Factor
52%
Androgen
46%
Biological Marker
41%
Cardiovascular Disease
40%
Non Insulin Dependent Diabetes Mellitus
38%
Systolic Heart Failure
35%
Randomized Clinical Trial
33%
Copeptin
31%
Atrial Natriuretic Factor
30%
Fatty Liver
27%
Adiponectin
26%
Insulin Resistance
25%
Inflammation
25%
Proadrenomedullin
23%
Adrenomedullin
22%
Hyperprolactinemia
22%
Gonadorelin Agonist
22%
Prevalence
17%
Nonalcoholic Fatty Liver
17%
Diabetes Mellitus
16%
Prostate Cancer
16%
Acromegaly
16%
Triptorelin
15%
Medicine and Dentistry
Congestive Heart Failure
74%
Androgen
59%
Liraglutide
55%
Placebo
50%
Adipose Tissue
34%
Randomized Clinical Trial
33%
Polycystic Ovary Syndrome
33%
Prevalence
31%
Natriuretic Factor
24%
Systolic Heart Failure
24%
Cardiovascular System
24%
Outpatient
22%
Orchiectomy
22%
Biological Marker
22%
Meta-Analysis
22%
Heart Left Ventricle Function
22%
Gonadorelin Agonist
22%
Brain Natriuretic Peptide
21%
Amino Terminal Sequence
21%
Glucagon Like Peptide 1
19%
Androgen Deprivation Therapy
18%
Prostate Cancer
17%
Acromegaly
16%
Heart Left Ventricle Ejection Fraction
16%
Dual-Energy X-Ray Absorptiometry
16%
Heart Function
15%
Insulin Resistance
15%